{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:50:08Z","timestamp":1791946208726,"version":"4.3.4"},"reference-count":21,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"This study was sponsored by Mitsubishi Tanabe Pharma America, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Neurodegenerative Disease Management"],"published-print":{"date-parts":[[2025,11,2]]},"DOI":"10.1080\/17582024.2025.2552610","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T08:47:29Z","timestamp":1756457249000},"page":"305-312","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Real-world safety and tolerability of intravenous edaravone in patients with amyotrophic lateral sclerosis"],"prefix":"10.1080","volume":"15","author":[{"given":"Agessandro","family":"Abrahao","sequence":"first","affiliation":[{"name":"University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Da Silva","sequence":"additional","affiliation":[{"name":"Inc","place":["Jersey City"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Ciepielewska","sequence":"additional","affiliation":[{"name":"Inc","place":["Jersey City"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorne","family":"Zinman","sequence":"additional","affiliation":[{"name":"University of Toronto","place":["Toronto, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1603471"},{"issue":"9","key":"e_1_3_6_4_1","first-page":"S175","article-title":"Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion","volume":"24","author":"Brooks BR","year":"2018","unstructured":"Brooks BR, Jorgenson JA, Newhouse BJ, et al. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion. Am J Manag Care. 2018;24(suppl 9):S175\u2013S186.","journal-title":"Am J Manag Care"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2021.2023190"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2022.2059380"},{"key":"e_1_3_6_7_1","volume-title":"(edaravone) IV and Radicava ORS\u00ae (edaravone) oral suspension. Prescribing information","author":"Radicava\u00ae","year":"2022","unstructured":"Radicava\u00ae (edaravone) IV and Radicava ORS\u00ae (edaravone) oral suspension. Prescribing information. Jersey City (NJ): Mitsubishi Tanabe Pharma Corporation; 2022 May."},{"key":"e_1_3_6_8_1","volume-title":"Prescribing information","author":"Rilutek\u00ae(riluzole)","year":"2016","unstructured":"Rilutek\u00ae(riluzole). Prescribing information. Cary (NC): Covis Pharmaceuticals, Inc.; 2016 Apr."},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuint.2015.07.024"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2006.03.008"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30115-1"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2017.1364269"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26740"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0258614"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2017.1365372"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/21678421.2019.1645858"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-022-00391-6"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.925"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.952"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27768"},{"key":"e_1_3_6_21_1","volume-title":"Relyvrio\u00ae (sodium phenylbutyrate and taurursodiol). Prescribing information","year":"2022","unstructured":"Relyvrio\u00ae (sodium phenylbutyrate and taurursodiol). Prescribing information. Cambridge (MA): Amylyx Pharmaceuticals, Inc.; 2022 Sep."},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2017.08.592"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ncn3.12490"}],"container-title":["Neurodegenerative Disease Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17582024.2025.2552610","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:33:54Z","timestamp":1763627634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17582024.2025.2552610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11,2]]}},"alternative-id":["10.1080\/17582024.2025.2552610"],"URL":"https:\/\/doi.org\/10.1080\/17582024.2025.2552610","relation":{},"ISSN":["1758-2024","1758-2032"],"issn-type":[{"value":"1758-2024","type":"print"},{"value":"1758-2032","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=inmt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}